April 16, 2024
Reporter, D.C. Diagnosis Writer

Hello and happy Tuesday, D.C. Diagnosis readers! Should antidepressants be available over the counter? STAT readers respond to that and other science and policy debates. As always, send tips, news and story thoughts to sarah.owermohle@statnews.com.

on the hill

Chuck Schumer’s broken promise on insulin pricing

We here at D.C. Diagnosis are old enough to remember when Senate Majority Leader Chuck Schumer first promised to hold a vote to ensure no patient with insurance paid more than $35 per month for insulin — back in February 2022.

Now, more than two years later, he still hasn’t made senators take a vote. My colleague Rachel Cohrs Zhang has a deep dive on how insulin copay caps have become a victim of Democrats’ piecemeal success so far. Some people like seniors are protected. Around half of U.S. states have passed their own laws. Drugmakers have taken voluntary action. But Democrats can’t seem to get across the finish line and give legal protections to everyone with insurance, not to mention the uninsured.

To complicate matters further, there are deep divisions that would make passing legislation an uphill slog. Republicans don’t agree. Drugmakers and insurers disagree. Patient advocacy groups disagree. Heck, even Senate Democrats are at odds. Read Rachel’s accountability reporting here.


coronavirus

Covid panel targets science journals 

The House subcommittee investigating the Covid-19 pandemic is back again with a hearing today on the relationship between medical journals and the government — and whether the journals were “inappropriately influenced by a political agenda,” according to Chair Brad Wenstrup (R-Ohio). 

But it’ll be a relatively limited affair: Only one of the three journal editors invited to testify, Science’s Holden Thorp, will be there. Nature’s Magdalena Skipper and The Lancet’s Richard Horton declined to show. 

Democrats on the committee have decried the parade of hearings and closed-door testimonies under GOP leadership, which have roped in more than a dozen current and former officials from HHS leaders to now-retired Anthony Fauci and Francis Collins. Today’s hearing is the latest example of House Republicans’ “extreme, political witch hunt” that is “sowing mistrust,” ranking member Rep. Raul Ruiz (D-Calif.) told DCD in a statement.



food fights

A masterclass in political spin

Grocers are backing a new bill entitled the “Food Traceability Enhancement Act,” which they say will help improve food safety. There’s just one problem: It would gut the policy that it is claiming to “enhance,” my colleague Nick Florko writes.

The bill would exempt grocers from key provisions of the FDA rule that requires grocers and others in the food supply chain to keep detailed records of how food was handled and stored during transportation and processing. It’s a brazen response to industry complaints that the FDA’s proposal is far too complicated and costly for most stores to implement in the timeframe the agency has proposed.

Why would any lawmaker agree to introduce a bill that does the exact opposite of what it purports to do – especially on a topic as life-or-death as food safety? A spokesperson for the sponsor of the bill, Rep. Scott Franklin, argued that the lawmaker “does not disagree with the intent” of the FDA’s policy, and that his legislation would help companies “comply with the mandate so measurable progress can be made.” Click here to find out more.

 


medicare money

Pharmacists attempt to turn up PBM heat 

Express Scripts is squeezing independent pharmacies with unfair rates and untransparent “bonus pool” fees, the national pharmacy lobby alleges in a new letter to the PBM’s executives — that was also dispatched to CMS officials and leadership of all the major congressional committees on health policy. 

It’s the latest shot in a battle over drug pricing reform that Congress has put off, for now. But while some of the problems cited by the National Community Pharmacy Association would be addressed by the two bills on the table, the lobby says Express Scripts is already running afoul of CMS regulations and independent pharmacies are shuttering as a result. And despite Congress’ hazy timeline for legislation, federal pressure on the PBM industry has been building. After all, White House officials heard last month that PBMs are “everything wrong with this industry.” 

The PBM lobby are looking to fight back with a fly-in to congressional offices this week emphasizing their work with rural pharmacies, the very shops at the heart of the NCPA letter. One example they cite is the new arm of Express Scripts, or ESI, exploring independent pharmacy reimbursements.

"To comply with the new CMS rules, our approach is intended to keep pharmacy payments equivalent while maintaining our commitment to monitoring pharmacy quality," which includes a "value-based program," an ESI spokesperson said.

Those efforts don’t have pharmacists convinced: “Unfortunately, and ironically, business conditions dictated by ESI to independent pharmacies have only gotten worse since ESI’s announcements,” NCPA CEO Douglas Hoey wrote in his letter.


telehealth talk

FTC data crackdowns continue

Telehealth company Cerebral will limit the consumer health data it uses for advertising purposes — and pay a fine — under a new FTC order. The plan, which only applies to Cerebral, must still be approved by a federal court before it goes into effect — but the company has already agreed to it, Katie Palmer and Mohana Ravindranath report.

This is just the latest in a series of federal actions cracking down on health data privacy online. The current commissioners have pledged to shore up gaps between federal privacy laws governing providers and payers and those protecting consumer services.

Cerebral is a startup best known for dispensing counseling services and prescriptions for conditions like anxiety and depression. But it’s far from the only company that could find itself in hot water: An investigation by STAT and the Markup found that dozens of telehealth companies, including Cerebral, were leaking sensitive health data to third parties. More from Kate and Mohana.


More around STAT
Check out more exclusive coverage with a STAT+ subscription
Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

What we’re reading

  • Can investing in infectious disease pay off? Vir Biotechnology’s tightrope walk shows it’s a struggle, STAT
  • Francis Collins: Why I’m going public with my prostate cancer diagnosis, The Washington Post
  • Mass General Brigham is ready to move on without Dana-Farber, CEO says, STAT
  • How to die in good health, The New Yorker

Thanks for reading! More on Thursday,


Enjoying D.C. Diagnosis? Tell us about your experience
Continue reading the latest health & science news with the STAT app
Download on the App Store or get it on Google Play
STAT
STAT, 1 Exchange Place, Boston, MA
©2024, All Rights Reserved.